Literature DB >> 32648210

Prognostic Role of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Immunohistochemical Expression in Patients with Resected Gastric Carcinomas.

Cristina Díaz Del Arco1,2, Lourdes Estrada Muñoz3, Rodrigo Barderas Manchado4, Alberto Peláez García5, Luis Ortega Medina6,7, Elena Molina Roldán7, Guillermo Solís Fernández4, Soledad García Gómez de Las Heras3, Mª Jesús Fernández Aceñero6,8.   

Abstract

Aryl hydrocarbon receptor (AHR) interacting protein (AIP) is a chaperone which binds to inactive AHR in the cell cytoplasm. AHR is best known for mediating the toxicity of halogenated aromatics, but it has also been linked to carcinogenesis and tumor progression in several tumor types. Our aims are to assess the features of AIP immunohistochemical (IHC) staining and to evaluate its possible role as a prognostic marker in gastric cancer (GC). Retrospective study of 147 cases of resected GC. Clinicopathological features were collected, tissue microarrays were constructed for AIP IHC and statistical analysis were performed. AIP staining was observed in 50.3% of tumors. All AIP-positive cases exhibited cytoplasmic or membranous staining, variably associated with nuclear co-staining. 93.2% of AIP-positive tumors showed AIP immunoreactivity in 100% of cells. Staining intensity was mild, moderate and intense in 33.8%, 13.5% and 52.7% of cases. Tumors were stratified according to AIP staining intensity into low expression (no or mild AIP immunoreactivity) and high expression (moderate or intense AIP immunoreactivity). 36.6% of our cases showed high AIP expression. High AIP expression was significantly and independently correlated to tumor progression and cancer death. Tumors with high AIP expression showed lower survival and higher progression rates. AIP expression might be useful for determining GC prognosis. More studies are needed to clarify the role of AHR pathway in GC, AIP expression and its potential use as a surrogate marker for selecting patients for AHR modulation therapy.

Entities:  

Keywords:  AIP; Aryl hydrocarbon receptor interacting protein; Gastric cancer; Immunohistochemistry; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 32648210     DOI: 10.1007/s12253-020-00863-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  3 in total

1.  A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors.

Authors:  Patrik Andersson; Jacqueline McGuire; Carlos Rubio; Katarina Gradin; Murray L Whitelaw; Sven Pettersson; Annika Hanberg; Lorenz Poellinger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-09       Impact factor: 11.205

Review 2.  Aryl hydrocarbon receptor and lung cancer.

Authors:  Junchieh J Tsay; Kam-Meng Tchou-Wong; Alissa K Greenberg; Harvey Pass; William N Rom
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

3.  Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.

Authors:  Marie-Lise Jaffrain-Rea; Mariolina Angelini; Donatella Gargano; Maria A Tichomirowa; Adrian F Daly; Jean-François Vanbellinghen; Emanuela D'Innocenzo; Anne Barlier; Felice Giangaspero; Vincenzo Esposito; Luca Ventura; Antonietta Arcella; Marily Theodoropoulou; Luciana A Naves; Carmen Fajardo; Sabina Zacharieva; Vincent Rohmer; Thierry Brue; Alberto Gulino; Giampaolo Cantore; Edoardo Alesse; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2009-06-25       Impact factor: 5.678

  3 in total
  1 in total

1.  Aryl-hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis.

Authors:  Ana Montero-Calle; Maricruz Sánchez-Martínez; Guillermo Solís-Fernández; Alberto Peláez-García; María Jesús Fernández-Aceñero; Pilar Pallarés; Miren Alonso-Navarro; Marta Mendiola; Jelle Hendrix; David Hardisson; Rubén A Bartolomé; Johan Hofkens; Susana Rocha; Rodrigo Barderas
Journal:  Br J Cancer       Date:  2022-03-28       Impact factor: 9.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.